Sarah Zhang

Sarah Zhang is a staff writer at The Atlantic, where she covers health and medicine. Her work has appeared in The New York Times, Slate, and Wired. She has a master's degree in journalism from Columbia University and a bachelor's degree in English from the University of Pennsylvania. Zhang's reporting focuses on the latest developments in medical research and how they impact public health policy.

Biography:  https://www.theatlantic.com/author/sarah-zhang/?lctg=6050f061f98ec7553cebfa1e

67%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.

Bias

50%

Examples:

  • The article does not take a clear stance on the issue, which could be seen as lacking in-depth analysis.

Conflicts of Interest

100%

Examples:

  • No conflicts of interest detected.

Contradictions

60%

Examples:

  • The high cost of obesity drugs may limit access and affordability for patients.
  • The statement contradicts information provided by other sources that Ozempic and similar drugs are meant to be taken for life or possibly a lifetime.

Deceptions

45%

Examples:

  • The article uses quotes from experts to present both sides of the issue without clearly stating the author's stance.
  • The use of phrases like 'Now I've got to figure out, well, how do I treat them?' can be seen as an attempt to manipulate readers' emotions.

Recent Articles

New Study Shows Over One-Third of GLP-1 Drug Users Discontinue Medication Within a Year Due to Costs and Side Effects

New Study Shows Over One-Third of GLP-1 Drug Users Discontinue Medication Within a Year Due to Costs and Side Effects

Broke On: Friday, 24 May 2024 A recent study published in JAMA Network Open found that over one-third of patients discontinued use of GLP-1 weight-loss drugs like Wegovy and Ozempic within a year due to costs, gastrointestinal side effects, and availability issues. Obese individuals without type 2 diabetes were more likely to quit than those with diabetes. Despite potential health benefits, high costs and side effects pose challenges for long-term use.